Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity First-in-class, oral PKM2 modulator, SYX-5219, has the ...

The inflation-adjusted cost of developing a new drug now doubles roughly every nine years. To reverse this trend, the ...

The trial is funded through Abu Dhabi's Healthcare Research and Innovation FundClinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026MERTK-related retinitis pigmentosa aff ...

Sharp Therapeutics Corp. ("Sharp" or the "Company") (TSX-V: SHRX) (OTCQB: SHRXF), a biotechnology company developing small-molecule therapeutics for genetic diseases, announced today the appointment ...

The future of clinical research depends on people just as much as strong systems and processes. Learn what makes great ...

Pharma is understandably risk-averse, and many companies remain in pilot mode, running small experiments that never scale.

Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced the start of GMP ...

Acquisition adds further specialist biostatistics, data management, and medical writing expertise to Evestia Clinical’s full-service offering and strengthens its presence in Germany and across Europe ...

ORIC Pharmaceuticals, Inc. announced its clinical development plans for its lead programs, ORIC-944 and ORIC-114, while reporting financial results for the first quarter of 2025. The company presented ...

Werewolf Therapeutics provided a business update, announcing progress in their clinical trials for WTX-124, a conditionally activated therapeutic for cutaneous melanoma, with full enrollment in ...